# N4 Pharma in a stronger position for collaborations

- Link: https://www.directorstalkinterviews.com/n4-pharma-in-a-stronger-position-for-collaborations/412963340
- Published: 2021-02-24T07:36:58+00:00
- Author: Giles

**N4 Pharma Plc** (LON:N4P), the specialist pharmaceutical company developing Nuvec
®, a novel delivery system for cancer treatments and vaccines, has announced its
audited results for the year ended 31 December 2020.

> **Nigel Theobald, Chief Executive Officer of N4 Pharma Plc, commented:**
> “The last 12 months have seen us make considerable progress in the dispersion 
> and formulation work for Nuvec® which will put us in a stronger position for our
> collaboration discussions as we continue to present our data to potential licensing
> partners. The next few months will generate further important in vivo antibody
> response data using a SARS COV-2 plasmid both with our original and optimised 
> Nuvec® formulations.
> We have also recently announced that the European Patent Office has notified The
> University of Queensland of the intention to grant the patent that we have licensed
> the exclusive rights to. This has been followed more recently by the Australian
> patent office confirming its intention to grant a patent and we expect other key
> territories to follow suit in 2021. This again strengthens our commercial discussions.
> This is a pivotal time for the Company, we are now finalising the data we feel
> will give third parties the confidence to explore testing of Nuvec® with their
> own constructs and we continue to expand that dataset all the time.
> We are continuing work on other applications for Nuvec® both for cancer treatment
> and also to explore the potential for oral delivery of vaccines. This work on 
> oral delivery will continue in the background as there is much that needs doing
> to establish the potential for Nuvec® in this area as no one experiment will provide
> a definitive conclusion either way on this potential.”

**Chairman’s Report**

In the comparative year results N4 Biotech also forms part of the Group.  N4 Biotech
was dissolved on 14 January 2020.

N4 UK is a specialist pharmaceutical company engaged in the development of mesoparticulate
silica delivery systems to improve the cellular delivery and potency of vaccines.

The Board has not presented a Strategic Report for the year.  All relevant information
on the strategy and performance of the Group is included in the Chairman’s report
below and the Directors’ Report on page 9 of the annual report.

**Review of operations for the financial year ended 31 December 2020**

During the year to 31 December 2020, as anticipated, no revenue was generated by
the Group (31 December 2019: £nil).

The operating loss for the year was £1,564,421 (31 December 2019: £947,340 loss).
Expenditure was broadly in line with budget and increased in line with study results
determining the next expenditure requirements to progress work streams.

During the course of the year the Company raised in excess of £4.15m, through a 
placing of 50,731,250 new ordinary shares in May and a further 25,000,000 shares
in December with the remainder being through the exercise of warrants and options.
In total the Company issued 79,617,812 new ordinary shares of 0.4p in 2020.

Cash at the year-end stood at £3,555,579 (31 December 2019: £965,752). Our cash 
position is the strongest it has ever been and leaves us well positioned to complete
our current work streams, plan for follow on work and fund our costs in any initial
collaboration work.

**Key Operational Events and Opportunities**

The first part of 2020 saw the Group focus on the optimisation of Nuvec® starting
with the improved manufacture and dispersion of the particle. In parallel, we entered
into a research collaboration agreement with Nanomerics Limited (“Nanomerics”) to
focus on the stability of a number of different formulations of Nuvec® using both
a well characterised plasmid DNA and a novel small interfering RNA (siRNA). Whilst
these work streams remained ongoing, the advent of the Covid-19 pandemic presented
significant local and global challenges but also created an opportunity as to how
Nuvec® may be applied as a potential delivery technology to any of the multiple 
Covid-19 vaccines recently approved and in development across the world.

Whilst we did not initially envisage a material disruption to our studies, the scale
of lockdown created minor but inevitable delays to our optimisation work. As working
practices have evolved against the backdrop of the pandemic, these work streams 
are now very much on track and continue to expand our data set for Nuvec®. With 
such attention on Covid-19 and potential vaccines, we took the decision to undertake
a proof of concept study prior to a full _in vivo_ study to assess the efficacy 
of Nuvec® loaded with the Coronavirus plasmid DNA. This work was undertaken by an
experienced contract research organisation, Evotec, and concluded having demonstrated
the successful _in vitro_ transfection of HEK cells resulting in the decision to
move to a full _in vivo_ study as set out further below.

As announced previously our current strategy has been divided across three work 
streams:

1.   Completion of the optimisation work including the establishment of optimal 
dispersion, loading ratios and the tech transfer for consistent manufacture of naked
nanosilica particles;

2.   The scoping and implementation of our most comprehensive _in vivo_ study to
date; and

3.   Feasibility studies on other applications for Nuvec® such as for oral vaccines
and in oncology.

Updates on each stream are as follows:

**Optimisation and tech transfer**

Over the last 12 months, our program of optimisation work has been undertaken to
further characterise Nuvec® nanoparticulate silica with the objective of developing
a colloidally stable monodisperse formulation suitable for scaled manufacture.  
This work has been successful, and a process has been developed which results in
a monodisperse nanoparticulate formulation which can be freeze dried and reconstituted
without loss of colloidal stability. Importantly this formulation also retains _in
vitro_ transfection activity when stored dry for up to 14 days at 0-4C and room 
temperature, before reconstitution.  Longer term stability assessment will be conducted
in due course.

Other studies have also been conducted to optimise the PEI content, determine need
for phosphonation and to assess the optimal pH and buffer capacity of the medium
in which Nuvec® is dissolved.

In September we appointed Ardena as our contract development and manufacturing organisation(‘
CDMO’) partner for the technology transfer and upscaling manufacturing of Nuvec®.
Work has been on schedule and Ardena is currently working on the process optimisation
and scale-up resulting in the manufacture and analysis of a non-GMP 50g batch of
Nuvec® prior to moving towards the manufacture, testing and product certification
of Nuvec® for GMP status.

**In Vivo study plans and implementation**

The _in vivo_ study to compare the reactions of the original Nuvec® loaded with 
the Coronavirus plasmid and another generic plasmid in generating relevant antibodies,
has recently commenced at the University of Queensland. The commencement of this
work is a little later than originally envisaged, following delays in obtaining 
the relevant customs clearance to transport the Coronavirus plasmid expressing the
spike protein into Australia.

Having optimised Nuvec® as described above, we are now planning the commencement
of further _in vivo_ studies to determine whether the improved properties noted 
_in vitro_ can also be seen _in vivo_. These studies will be undertaken by Evotec
with study initiation expect by early March.

The optimised Nuvec® _in vivo_ studies in mice are planned to assess the following
points:

(1) to determine antibody production following dosing with optimised Nuvec®;

(2) To explore dose relationship to determine minimum and maximum plasmid dose required
for effect.  This information may also provide information on dose-sparing i.e. 
reduced DNA use; and

(3) to confirm activity is retained after freeze drying and reconstitution at different
intervals.

These studies will again involve the Coronavirus plasmid and another generic plasmid.
Results from both studies should be known during the first half of 2021.

**Oral and oncology applications**

In November we announced the launch of our Nuvec® oncology treatment programme with
Nanomerics Limited. The programme will explore the role of Nuvec® as a delivery 
system for DNA and SiRNA in a proof of concept preclinical tumour model. The two-
stage programme will focus initially on the formulation of Nuvec® with a therapeutic
DNA plasmid, whilst stage two will see the candidate formulation evaluated _in vivo_
in a subcutaneous tumour model to examine tumour regression following multiple local
or systemic injections.

Our work to understand the viability of Nuvec® in oral delivery remains ongoing 
and is currently focussed on extensive _in vitro_ work. In particular we are assessing
the ability to transfect epithelial cells in the gut as well as the impact of mucus
and other variables. Whilst the commercial potential of successfully demonstrating
Nuvec’s® efficacy in oral delivery would be huge we are still at the early stages
of establishing whether it is feasible. As this work continues in the background
our primary focus remains Nuvec’s® potential use to improve the cellular delivery
and potency of vaccines.

The strengthening of our balance sheet through the funds raised in May of this year,
means that we are well funded to complete all our currently planned work streams
whilst the recent placing in December means we can plan for more supplementary studies
whilst being able to budget for the next stage of work following the current _in
vivo_ studies and the oral and oncology work.

**Intellectual Property**

As announced on 11 February the University of Queensland (“UQ”) has been notified
by the European Patent Office (“EPO”) of its intention to grant a European Patent
in relation to Nuvec® specifically in respect of its composition, particulate materials
and methods for making the particulate materials (the “Patent”). N4 Pharma has the
exclusive worldwide rights to Nuvec® for therapeutic uses in humans and animals.

Having received the notification, the next steps prior to formal grant will require
UQ to confirm the particulars and translations with the EPO prior to publication
of the grant after which the Patent will be validated on a country by country basis
throughout Europe as determined by UQ and the Company. This process, resulting in
the full grant of the Patent in each chosen territory, should take six to eight 
months.

The Patent application process for other jurisdictions remains on course and the
board is optimistic that now the Patent has successfully been processed by the EPO
other jurisdictions should follow suit in due course. In line with this optimism
I am delighted to announce that the Australian patent office has also notified UQ
of its intention to grant an Australian Patent.

**Board Changes**

On 15 July 2020 Luke Cairns, previously a Non-Executive Director, became an Executive
Director, overseeing the Group’s finance, corporate and investor relations activities
allowing Nigel Theobald, Chief Executive Officer, more time to focus on driving 
the Group’s development programmes and potential commercial collaborations.

**Future Prospects**

What is increasingly clear with the ongoing Coronavirus pandemic is that even with
the great success of the recently approved vaccines, as the virus evolves, so will
the vaccines and there will be multiple iterations in the years to come. Cost effective
storage, transportation and effective delivery are areas where any improvements 
could have a material impact on the successful role out of vaccines, particularly
in emerging markets where wide scale accessibility to vaccines remains challenging.
It is our hope that as we look to conclude our most comprehensive Nuvec® studies
to date, we will be able to present Nuvec® as a viable delivery solution to vaccine
developers.

It is important to stress that we see Nuvec® as a platform delivery technology and
whilst it may suit some plasmids better than others it is our intention that it 
be used across multiple vaccines and not just those addressing Coronavirus. Through
our oral studies we are also examining how Nuvec® could simplify the way vaccines
are administered. Whilst the majority of our data has been gathered using plasmid
DNA we are increasing our work with mRNA. Together with our oncology programme, 
2021 could turn out to be a pivotal year for N4 Pharma, as our various applications
for Nuvec® advance to the point where we can engage further with potential collaborators
and partners. In parallel we are also exploring other assets that could be complimentary
to Nuvec®.

On behalf of the Board, I would like to thank all of our shareholders for their 
continued patient support and look forward to providing further updates on our progress.

By order of the Board

John Chiplin

Chairman

Share on:
